問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



Chi Mei Hospital, Liouying

  • 0

    Total Beds

  • 0

    Total Doctors

  • pidb_editor
  • 736Tainan CityTainan Liouying

Recruiting Trial

125Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

263Cases

2014-07-31 - 2020-12-25

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2014-02-19 - 2017-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2009-02-01 - 2017-05-28

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated3Sites

Suspended4Sites

2010-08-26 - 2015-05-01

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2019-03-01 - 2022-12-31

Phase III

A Phase 3, double-blind, multicenter, placebo-controlled study of PledOx used on top of modified FOLFOX6 (5?FU/FA and Oxaliplatin) to prevent chemotherapy induced peripheral neuropathy (CIPN) in patients with first-line metastatic colorectal cancer

  • Condition/Disease

    Prevent chemotherapy-induced peripheral neuropathy (CIPN)

  • Test Drug

    PledOx

Participate Sites
4Sites

Terminated3Sites

王照元
Kaohsiung Municipal Gangshan Hospital

未分科

2019-03-01 - 2021-12-31

Phase III

A Phase 3, double-blind, multicenter, placebo-controlled study of PledOx used on top of modified FOLFOX6 (5-FU/FA and Oxaliplatin) to prevent chemotherapy induced peripheral neuropathy (CIPN) in the adjuvant treatment of patients with Stage III or high-risk Stage II colorectal cancer

  • Condition/Disease

    Prevention of chemotherapy induced peripheral neuropathy (CIPN) (chemotherapy induced peripheral neuropathy)

  • Test Drug

    PledOx

Participate Sites
4Sites

Terminated3Sites

王照元
Kaohsiung Municipal Gangshan Hospital

未分科

2020-05-01 - 2020-06-29

Phase III

A Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trial of CS1001 as Consolidation Treatment in Subjects with Locally Advanced/Unresectable (Stage III) Non-Small Cell Lung Cancer that Hasn’t Progressed After Prior Concurrent/Sequential Chemoradiotherapy.

  • Condition/Disease

    Non-Small Cell Lung Cancer Stage III

  • Test Drug

    CS1001

Participate Sites
6Sites

Recruiting6Sites

2008-03-01 - 2011-12-03

Phase III

A Randomized , Multicenter, Open-label, Phase III Study of Lapatinib in Combination with weekly Paclitaxel versus weekly Paclitaxel alone in the second line treatment of ErbB2 amplified Advanced Gastric Cancer

  • Condition/Disease

    Gastric Cancer

  • Test Drug

    Lapatinib

Participate Sites
6Sites

Terminated6Sites

2008-05-01 - 2012-05-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Terminated11Sites

2006-10-01 - 2009-04-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

1 17 18 19 20 21 27
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB